# EDGAR Filing Document

**Accession Number:** 0000083246
**File Stem:** 0001104659-23-009798
**Filing Date:** 2023-2
**Character Count:** 13063
**Document Hash:** 16bba4c1edad7c529415546a10df0196
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-009798.hdr.sgml**: 20230202

**ACCESSION NUMBER**: 0001104659-23-009798

**CONFORMED SUBMISSION TYPE**: FWP

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230202

**DATE AS OF CHANGE**: 20230202

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HSBC USA INC /MD/
- **CENTRAL INDEX KEY:** 0000083246
- **STANDARD INDUSTRIAL CLASSIFICATION:** NATIONAL COMMERCIAL BANKS [6021]
- **IRS NUMBER:** 132764867
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-253385
- **FILM NUMBER:** 23580009

**BUSINESS ADDRESS:**
- **STREET 1:** 452 FIFTH AVE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** 212-525-5000

**MAIL ADDRESS:**
- **STREET 1:** 452 FIFTH AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HSBC USA INC /MD/
- **CENTRAL INDEX KEY:** 0000083246
- **STANDARD INDUSTRIAL CLASSIFICATION:** NATIONAL COMMERCIAL BANKS [6021]
- **IRS NUMBER:** 132764867
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** FWP

**BUSINESS ADDRESS:**
- **STREET 1:** 452 FIFTH AVE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** 212-525-5000

**MAIL ADDRESS:**
- **STREET 1:** 452 FIFTH AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; ![](image_004.jpg)<br>| &nbsp;&nbsp; Structured Investments<br> Opportunities in U.S. Equities | &nbsp;&nbsp; Free Writing Prospectus<br> Registration Statement No. 333-253385<br> February 2, 2023<br> Filed Pursuant to Rule 433 |

---

**Contingent Income Callable Securities due February 13, 2025**

**Based on the S&P 500<sup>®</sup> Index** 

**Principal at Risk Securities**

This document provides a summary of the terms of the Contingent Income Callable Securities, which we refer to as the securities. Investors must carefully review the accompanying free writing prospectus referenced below, prospectus, prospectus supplement and Equity Index Underlying Supplement, and the "Risk Considerations" on the following page, prior to making an investment decision.

&nbsp;&nbsp;&nbsp;INDICATIVE TERMS

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Issuer:** | HSBC USA Inc. ("HSBC") |
| &nbsp;&nbsp;**Maturity date\*:** | February 13, 2025, subject to adjustment as described in the accompanying Equity Index Underlying Supplement  |
| &nbsp;&nbsp;**Underlying index:** | The S&P 500<sup>®</sup> Index (Bloomberg symbol: SPX) (the "SPX" or the "underlying index"). For more information about the underlying index, including historical performance information, see the accompanying free writing prospectus.<br>|
| &nbsp;&nbsp;**Early redemption <br> notice dates:** | The observation dates, beginning on May 10, 2023. |
| &nbsp;&nbsp;**Observation <br> Dates:** | Quarterly, on May 10, 2023, August 10, 2023, November 10, 2023, February 12, 2024, May 10, 2024, August 12, 2024, November 11, 2024 and February 10, 2025 (the valuation date) |
| &nbsp;&nbsp;**Contingent <br> payment dates:** | Quarterly, on May 15, 2023, August 15, 2023, November 15, 2023, February 15, 2024, May 15, 2024, August 15, 2024, November 14, 2024 and February 13, 2025 (the maturity date) |
| &nbsp;&nbsp;**Early redemption:** | The securities may be redeemed **at our discretion** on any early redemption notice date, for the principal amount plus the contingent quarterly payment for the related quarterly observation date if any. In order to redeem the securities, we or the calculation agent will distribute written notice to The Depository Trust Company of our intent to call the securities on or prior to the applicable early redemption notice date. We or the calculation agent will have no independent obligation to notify you directly and you should expect to receive such notifications from your broker.<br>|
| &nbsp;&nbsp;**Early redemption <br> price:** | The sum of the stated principal amount and the contingent quarterly payment, if any, for the related quarterly observation date. This amount will be paid on the contingent payment date following the applicable early redemption notice date. |
| &nbsp;&nbsp;**Contingent <br> quarterly<br> payment:** | · Subject to early redemption, if the official closing level for the underlying index on the relevant quarterly observation date is greater than or equal to the coupon barrier level, we will pay a contingent quarterly payment at an annual rate of at least 8.35% of the stated principal amount per security (corresponding to $20.875 (or 2.0875%) per quarter per security) on the related contingent payment date. The actual contingent quarterly payment will be determined on the pricing date. If the official closing level of the underlying index on the relevant quarterly observation date is less than the coupon barrier level, no contingent quarterly payment will be made with respect to that quarterly observation date.<br> It is possible that the underlying index will remain below the coupon barrier level for extended periods of time or even throughout the entire term of the securities, so that you will receive few or no contingent quarterly payments during the term of the securities.<br>|

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Payment at maturity:** | &nbsp;&nbsp;If the securities have not been previously redeemed, investors will receive a payment at maturity as follows: |

---

· If the final index level is **greater than or equal to** the downside threshold level: the stated principal amount *plus,* if
applicable, the final contingent quarterly payment.

· If the final index level is **less than** the downside threshold level: (i)
 the stated principal amount *multiplied* by (ii) the index performance factor. **In this case, the payment at maturity will be less than 75% of the stated principal amount of the securities and could be zero.** 

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Index performance <br> factor:** | &nbsp;&nbsp;final index level / initial index level |
| &nbsp;&nbsp;**Coupon barrier <br> level:** | &nbsp;&nbsp;75% of the initial index level |
| &nbsp;&nbsp;**Downside <br> threshold level:** | &nbsp;&nbsp;75% of the initial index level |
| &nbsp;&nbsp;**Initial index level:** | &nbsp;&nbsp;The official closing level on the pricing date. |
| &nbsp;&nbsp;**Final index level:** | &nbsp;&nbsp;The official closing level on the valuation date. |
| &nbsp;&nbsp;**Stated principal <br> amount:** | &nbsp;&nbsp;$1,000 per security |
| &nbsp;&nbsp;**Issue price:** | &nbsp;&nbsp;$1,000 per security |
| &nbsp;&nbsp;**Pricing date\*:** | &nbsp;&nbsp;February 10, 2023 |
| &nbsp;&nbsp;**Original issue: <br> date\*:** | &nbsp;&nbsp;February 15, 2023 (3 business days after the pricing date) |
| &nbsp;&nbsp;**Valuation date\*:** | &nbsp;&nbsp;February 10, 2025, subject to adjustment as described in the accompanying Equity Index Underlying Supplement |
| &nbsp;&nbsp;**Estimated initial <br> value:** | &nbsp;&nbsp;The estimated initial value of the securities is expected to be less than the price you pay to purchase the securities. The estimated initial value does not represent a minimum price at which we or any of our affiliates would be willing to purchase your securities in the secondary market, if any, at any time. The estimated initial value will be calculated on the pricing date and will be set forth in the pricing supplement to which this free writing prospectus relates. See "Risk Factors—The estimated initial value of the securities, which will be determined by us on the pricing date, is expected to be less than the price to public and may differ from the market value of the securities in the secondary market, if any." |
| &nbsp;&nbsp;**CUSIP / ISIN:** | &nbsp;&nbsp; 40441XK90 / US40441XK900<br>|
| &nbsp;&nbsp;**Free writing**<br> **prospectus:** | &nbsp;&nbsp;[https://www.sec.gov/Archives/edgar/data/83246/0001104<br> 65923009776/tm234869d42_fwp.htm](https://www.sec.gov/Archives/edgar/data/83246/000110465923009776/tm234869d42_fwp.htm) |

---

***\*The pricing date, original issue date and the other dates set forth above are subject to change, and will be set forth in the pricing supplement relating to the securities.***

&nbsp;&nbsp;&nbsp;&nbsp; **Risk Considerations**<br>It is important for you to understand that this offering summary does not contain all of the material information an investor should consider before investing in the securities, including a more complete description of the risks relating to the securities. This offering summary is not for distribution in isolation and must be read together with the accompanying free writing prospectus.<br>

---

| | |
|:---|:---|
|  | ***Risks Relating to the Structure or Features of the Securities*** |
| · | You may lose a significant portion or all of your initial investment. |
| · | You will not receive any contingent quarterly payment for any quarterly observation period where the official closing level of the underlying index on the relevant observation date is less than the coupon barrier level. |
| · | Investors will not participate in any appreciation of the underlying index, and your return on the securities is limited to the principal amount plus any contingent quarterly payments, regardless of any appreciation in the level of the underlying index. |
| · | The securities may be called prior to the maturity date. |
| · | The amounts payable on the securities are linked to the level of the underlying index on the relevant quarterly observation date. |
| · | Higher contingent quarterly payments or a lower downside threshold level are generally associated with an underlying index with greater expected volatility and therefore can indicate a greater risk of loss. |
|  | ***Risks Relating to the Underlying Index*** |
| · | Investing in the securities is not equivalent to investing in the securities included in the underlying index. |
| · | Adjustments to the underlying index could adversely affect the value of the securities. |
|  | ***General Risk Factors*** |
| · | Credit risk of HSBC USA Inc. |
| · | The estimated initial value of the securities, which will be determined by us on the pricing date, is expected to be less than the price to public and may differ from the market value of the securities in the secondary market, if any. |
| · | If HSBC Securities (USA) Inc. were to repurchase your securities immediately after the original issue date, the price you receive may be higher than the estimated initial value of the securities. |
| · | The price of your securities in the secondary market, if any, immediately after the pricing date is expected to be less than the price to public. |
| · | The market price of the securities will be influenced by many unpredictable factors. |
| · | The securities will not be listed on any securities exchange and secondary trading may be limited. |
| · | Hedging and trading activity by our affiliates could adversely affect the value of the securities. |
| · | The calculation agent, which is HSBC or one of its affiliates, will make determinations with respect to the securities. |
| · | The securities are not insured by any governmental agency of the United States or any other jurisdiction. |
| · | The U.S. federal income tax consequences of an investment in the securities are uncertain. |

---

**Tax Considerations**

You should review carefully the discussion in the accompanying free writing prospectus under the caption "Additional Information About the securities —Tax considerations" concerning the U.S. federal income tax consequences of an investment in the securities, and you should consult your tax adviser.

If there is any inconsistency between any terms herein and the free writing prospectus relating to the securities, the free writing prospectus shall prevail. The issuer has filed a registration statement (including a prospectus, prospectus supplement and Equity Index Underlying Supplement) with the Securities and Exchange Commission ("SEC") for the offering to which this preliminary free writing prospectus relates. Before you invest, you should read the free writing prospectus relating to the offering, and also the prospectus, prospectus supplement and Equity Index Underlying Supplement in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC's web site at https://www.sec.gov/edgar/search/. Alternatively, HSBC Securities (USA) Inc. or any dealer participating in this offering will arrange to send you the free writing prospectus, prospectus, prospectus supplement and Equity Index Underlying Supplement if you request them by calling toll-free **1-866-811-8049**.

### Attached PDF Documents

**Attachment 1:** `tm234869d44_fwp.pdf`

_No text found in this document._